Ielasi, L.; Tovoli, F.; Tonnini, M.; Stefanini, B.; Tortora, R.; Magini, G.; Sacco, R.; Pressiani, T.; Trevisani, F.; Garajová, I.;
et al. Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma. Cancers 2023, 15, 1523.
https://doi.org/10.3390/cancers15051523
AMA Style
Ielasi L, Tovoli F, Tonnini M, Stefanini B, Tortora R, Magini G, Sacco R, Pressiani T, Trevisani F, Garajová I,
et al. Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma. Cancers. 2023; 15(5):1523.
https://doi.org/10.3390/cancers15051523
Chicago/Turabian Style
Ielasi, Luca, Francesco Tovoli, Matteo Tonnini, Bernardo Stefanini, Raffaella Tortora, Giulia Magini, Rodolfo Sacco, Tiziana Pressiani, Franco Trevisani, Ingrid Garajová,
and et al. 2023. "Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma" Cancers 15, no. 5: 1523.
https://doi.org/10.3390/cancers15051523
APA Style
Ielasi, L., Tovoli, F., Tonnini, M., Stefanini, B., Tortora, R., Magini, G., Sacco, R., Pressiani, T., Trevisani, F., Garajová, I., Piscaglia, F., & Granito, A.
(2023). Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma. Cancers, 15(5), 1523.
https://doi.org/10.3390/cancers15051523
